Altimmune Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Did you know?
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedProfile
Valuation (TTM)
Market Cap$294.00M
P/E-3.34
EV—
P/B1.31
Shares Out104.25M
P/Sales8166.58
Revenue$36000.00
EV/EBITDA—
ALT (ALT) — Earnings Call Transcripts
No transcripts available yet
No earnings call transcripts are available for ALT yet. Check back after the next earnings report.
← Back to ALT overview